The central nervous system is an immune privileged organ in which inflammatory reactions are normally downregulated by mechanisms that are not completely understood. Transforming growth factor (TGF)-A2 is constitutively expressed in the adult central nervous system and little is known about its regulation and modulatory role during neuroinflammation. In this study, we show that TGFA2 mRNA and protein are downregulated in the acute phase of chronic relapsing experimental autoimmune encephalomyelitis, whereas the homologous cytokine TGFA1 is upregulated. To further characterize regulatory mechanisms, we resorted to an in vitro glial cell culture system. The proinflammatory cytokines IFNF and TNF> suppressed TGFA2 secretion by astrocytes, the major intracerebral producers of TGFA2. On the cellular level, activated microglia inhibited TGFA2 secretion but induced TGFA1 through soluble factors. On the other hand, TGFA2 influenced antigen-presenting cell functions of microglia by downregulating major histocompatibility complex class II expression and costimulatory/adhesion molecules, and thereby inhibited myelin basic protein-specific T cell proliferation. These data suggest that TGFA2 plays a central role in maintenance of the immune privilege of the central nervous system. Downregulation of astrocytic TGFA2 by T cell-and microglia-secreted cytokines appears to be a critical step in providing the grounds for acute and chronic neuroinflammation.
INTRODUCTION
The transforming growth factor As (TGFAs) belong to a family of multifunctional cytokines that regulate a wide range of biologic functions, including development, cell growth and differentiation, carcinogenesis, wound healing and fibrosis, and, lastly, inflammation and host defense (1) . The 3 isoforms of TGFA described in mammals (TGFA1, A2, and A3), each encoded by a different gene, show high structural homology, signal through the same receptor, and have similar cellular targets. However, they differ with regard to their selective expression, regulation, and biologic function (2) . Knockout mice for TGFA have nonoverlapping phenotypes, indicating diverse noncompensated functions of TGF family members (3Y5).
In the nervous system, TGFA2 mRNA and protein are constitutively expressed particularly by astrocytes in the white matter (2, 6) . In contrast, TGFA1 protein is completely absent from the normal adult central nervous system parenchyma (2) . TGFA2 plays a pivotal role in the creation and maintenance of an immunosuppressive environment in so-called immune-privileged sites such as the anterior chamber of the eye (7) and perhaps the central nervous system (8) . TGFA2 influences the behavior of antigen-presenting cells (APCs) in promoting differentiation of Ag-specific T cells into regulatory cells, leading to immune tolerance (7, 9Y11) . Moreover, TGFA2 inhibits IL-2-dependent proliferation of Ag-specific T cells (12) .
The aim of this study was to investigate the temporal expression and the cellular localization of TGFA2 in vivo during a chronic-relapsing form of experimental autoimmune encephalomyelitis (EAE). Furthermore, we set out to examine in vitro regulatory mechanisms within astrocytes, the main cellular source of TGFA2, and compare the findings with the expression of TGFA1.
Our results show that the 2 isoforms of TGFA are coordinately, but reciprocally, regulated during EAE. Constitutive TGFA2 expression in the central nervous system is downregulated by proinflammatory cytokines during the acute phase of EAE. Furthermore, we demonstrate that TGFA2 in vitro negatively influenced the Ag-presenting features of microglia, the principal APC of the central nervous system, and that the regulation of astrocytic TGFA2 expression involves complex T cell and astroglia/microglia interactions.
MATERIALS AND METHODS

Animals
Female Dark Agouti rats, 8 to 10 weeks old, were obtained from Harlan (Borchen, Germany). One-or 2-dayold newborn Lewis rats were obtained from Charles River (Sulzfeld, Germany). All experiments were approved by the Regierung of Unterfranken and performed according to the guidelines for animal experimentation.
Experimental Autoimmune Encephalomyelitis Induction
Chronic relapsing EAE was induced in 10-to 12-week-old female Dark Agouti rats by immunization with 75 Kg human recombinant extracellular myelin oligodendrocyte glycoprotein (MOG) (kindly provided by Dr. A. Weishaupt, Department of Neurology, University of Würzburg, Germany) (13, 14) emulsified 1:1 in complete Freund_s adjuvant (CFA) containing 225 Kg heat-killed Mycobacterium tuberculosis (H37Ra; Difco Laboratories, Detroit, MI) into both hind footpads (15) .
Animals were weighed and examined daily for clinical signs of EAE according to the following scale: 0, no abnormality; 1, flaccid tail; 2, hind limb weakness; 3, hind limb paralysis; 4, hind and fore limb paralysis; and 5, moribund state.
After the rats were killed, molecular and immunohistochemical studies were done at different times after immunization after the appearance of clinical signs: day 10, incipient disease (clinical score 1); day 13, first peak of disease (clinical score 4Y5); day 17, remission phase (clinical score 1Y2); day 24 and day 27, relapse (clinical score 4Y5). Nonimmunized rats were used as controls.
Immunohistochemistry
At days 10, 13, 17, 24, and 27 after immunization, rats were deeply anaesthetized and perfused through the left ventricle with Ringer solution followed by cold 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS; pH 7.4). Lumbar spinal cords were removed, postfixed for 2 hours in 4% paraformaldehyde at 4-C, and routinely embedded in paraffin. Five-micron-thick sections were stained with hematoxylin and eosin and Luxol fast blue to assess inflammation and demyelination, respectively. In adjacent serial sections, immunohistochemistry was performed with antibodies against the following targets: macrophages/activated microglia (ED1, 1:500; Serotec, Oxford, UK), T cells (B115-1, 1:500; HyCult Biotechnology, Holland), glial fibrillary acidic protein (GFAP, 1:500; DAKO, Glostrup, Denmark), TGFA1 (1:100), and TGFA2 (1:100/ 1:200) (Santa Cruz Biotechnology, Santa Cruz, CA). Deparaffinized sections were preincubated with 10% normal goat serum and incubated overnight with the primary antibody optimally diluted in Tris-buffered saline/1% bovine serum albumin. After washing, sections were treated with methanol/peroxide (10:1 v/v) to quench endogenous peroxidase and then incubated with biotinylated secondary Ab (Vector Laboratories, Burlingame, CA) and avidinY biotinYperoxidase complex reagent (DAKO) according to the manufacturer's instructions. 3,3-diaminobenzidine (Kem En Tec Diagnostics, Copenhagen, Denmark), in the presence of 0.03% H 2 O 2 , was used as substrate for staining reactions. For TGFA1 and TGFA2 immunohistochemistry, after deparaffinization, sections were incubated 30 minutes in an alkaline 10-mM sodium citrate solution maintained at 80-C to retrieve antigens (16) and then stained as described. In double-labeling experiments for colocalization of TGFA2 and GFAP, an Alexa-594-conjugated goat anti-rabbit secondary antibody (1:600) and an Alexa-488-conjugated monoclonal mouse anti-GFAP (1:100) were used (both from Molecular Probes, Eugene, OR) (17) . DAPI (1:50.000; Molecular Probes) was used for nuclear counterstaining. For negative controls, the primary antibody was omitted from the diluent.
Real-Time Quantitative Polymerase Chain Reaction
After anesthesia, rats were perfused intracardially with cold PBS. Lumbar spinal cords were collected and preserved in RNALater (Ambion, Huntingdon, UK) at j20-C until RNA extraction. Tissue homogenization and RNA isolation were performed using the TRIzol reagent (Invitrogen, Karlsruhe, Germany) according to the manufacturer's instructions.
Relative levels of TGFA1 and TGFA2 mRNA were quantified with real-time quantitative reverse transcriptaseY polymerase chain reaction using the fluorescent TaqMan technology as described in detail elsewhere (18) . Briefly, 250 ng of total RNA were reverse-transcribed with the TaqMan Reverse Transcription Reagents (Applied Biosystems, Darmstadt, Germany) according to the manufacturer's protocol using random hexamers. Polymerase chain reaction primers and probes specific for rat TGFA1 and 18s rRNA were obtained as TaqMan Predeveloped Assay Reagents for gene expression (Applied Biosystems). For the amplification of TGFA2, specific primers (forward 5 ¶-TCTGGAACCACT-GACCATCCT-3 ¶ [corresponding to nt. 1153Y1173 of rat TGFA2 mRNA, Gen Bank AF135598]; reverse 5 ¶-TCGATCTT-GGGCGTATTGC-3 ¶, nt. 1203Y1185) were applied as previously described (19) . 18s rRNA was used as an endogenous control to normalize the amount of sample RNA. The polymerase chain reaction was performed with equal amounts of cDNA in the GeneAmp 7700 sequence detection system (Applied Biosystems) using the TaqMan Universal PCR Master Mix (Applied Biosystems) according to the manufacturer's instructions. Reactions (total volume 50 KL) were incubated at 50-C for 2 minutes at 95-C for 10 minutes followed by 40 cycles of 15 seconds at 95-C and 1 minute at 60-C. Water controls were included to ensure specificity. Each sample was measured in triplicate and data points were examined for integrity by analysis of the amplification plot. The comparative Ct method was used for relative quantification of gene expression (20) .
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were carefully freed of meninges, chopped, and dissociated by mild trypsinization procedure. The cell suspensions was then seeded into 75-mm 2 flasks (4 hemispheres/ flask) and grown at 37-C in a 95% air/5% CO 2 humidified atmosphere in BME (GIBCO, Karlsruhe, Germany) containing 10% fetal calf serum (FCS) (Sigma, Schnelldorf, Germany), 2 mM Glutamine, penicillin (100 U/mL), and streptomycin (100 Kg/mL). The medium was replaced every 3 days. After 10 to 12 days, microglial cells were detached from the mixed glial cell cultures by shaking and seeded on an FCS-coated culture flask for 1 hour, then nonadherent cells were discarded and microglia were detached by trypsinization (21) .
For preparation of astrocyte cultures, 10-day-old primary mixed glial cell cultures were shaken to discard microglia. The remaining adherent cells were detached with Trypsin 0.25/EDTA (GIBCO) and the resulting cell suspension was left at room temperature in uncoated Petri dishes for 20 minutes to allow adherence of microglia to the plastic surface. This adhesion step was performed twice, and the supernatant containing the nonadherent cells were collected and centrifuged; the cells were resuspended and seeded in a 24-well plate (5 Â 10 5 cells/well) and allowed to adhere overnight before starting experiments (22) . In some cultures, FCS-containing medium was replaced by a serum-free chemically defined medium containing the G5 supplements (GIBCO). The purity of the astrocyte and microglia populations was determined by immunofluorescence and flow cytometry after staining with anti-GFAP antibody (DAKO) and anti-ED1 antibody (Serotec) to identify astrocytes (>98% GFAP+) and microglia (>95% ED1+), respectively.
Cocultures of astrocytes and microglia were established in 24-well plates by seeding increasing numbers of microglia (from 10 6 cells/well) were cultured in G5 medium for 24 hours and the supernatants were harvested, centrifuged, and added to freshly established astrocyte cultures.
TGFA1 and TGFA2 Enzyme-Linked Immunosorbent Assay
For the generation of culture supernatants, primary rat astrocytes were incubated in G5 medium in the absence or presence of the following stimulating agents: LPS (10Y100 ng/mL; GIBCO), recombinant rat TNF> (10Y100 ng/mL), recombinant rat IFNF (10Y100 ng/mL), recombinant rat IL-10 (0.2Y20 ng/mL), recombinant rat IL-18 (0.1Y100 ng/mL), and recombinant rat IL-1A (1Y100 ng/mL), all from R&D Systems (Wiesbaden, Germany). After 24 and 44 to 48 hours, supernatants from duplicate cultures were harvested, centrifuged, and stored at Y80-until use. Total (active and latent) TGFA2 and TGFA1 secreted in culture supernatants were quantified by specific enzyme-linked immunosorbent assay (Promega, Mannheim, Germany) with a detection limit of 15 to 30 pg/mL.
Flow Cytometric Analysis
Immunocytofluorescence staining was performed on microglia cultured for 24 hours in the absence or presence of porcine TGFA2 (5 ng/mL) and/or recombinant rat IFNF (10 ng/mL), both from R&D Systems (Wiesbaden, Germany). Cells were collected, washed, and incubated with 10% goat serum PBS to block unspecific staining 10 minutes at 4-C. Cells were then stained with the following fluorochrome-conjugated mAb at optimal dilutions (from BD Biosciences, Heidelberg, Germany): hamster anti-rat CD40 FITC (HM40-3, IgM); as control, cells were also stained with fluorescein isothiocyanate conjugated hamster IgM isotype control (from BD Biosciences). For RT1D class-II (OX-17), CD80 (B7-1), CD86 (B7-2), CD54 (ICAM-1) staining, cells were incubated first with mouse anti-rat OX-17 (MRC OX-17, IgG1; Serotec), mouse anti-rat CD80 (3H5, IgG1; BD), mouse anti-rat CD86 (24F, IgG1; BD), mouse anti-rat CD54 (1A29, IgG1; BD), and then with fluorescein isothiocyanate conjugated rat antimouse IgG1 (BD). Incubation with the secondary Ab was used as negative control. One color analysis was performed on a FACSCalibur using CellQuest (Becton Dickinson, Heidelberg, Germany) with a minimum of 5,000 events counted.
Antigen Presentation
Microglia (10 2 Y10 3 /well) were seeded in a 96-well flat-bottom tissue culture plate in the presence or absence of porcine TGFA2 (5 ng/mL) and/or recombinant rat IFNF (10 ng/mL) in G5 serum-free medium and incubated for 24 hours. Cells were then washed 3 times to remove stimulating agents. Encephalitogenic myelin basic protein (MBP)-specific T cells from line MBP13 were harvested at day 6 or 7 after restimulation and added (5 Â 10 4 /well) in serum-free RPMI to microglial cells in the absence and presence of guinea pig MBP (10 Kg/mL). After 12 to 16 hours, cells were pulsed with 0.2 KCi 3H-thymidine. Proliferation was measured by 3H-thymidine incorporation during the last 18 to 24 hours of a 36-to 40-hour incubation period. Radioactivity was detected by a Wallac Betaplate scintillation counter and was expressed as mean cpm T standard error of mean.
Statistics
Data analysis was performed using Prism 4.0 (Graph Pad Software, San Diego, CA). Polymerase chain reaction data from EAE rats at different time points were analyzed by 2-way analysis of variance followed by the Bonferroni corrections for multiple testing. Cytokine concentrations in experimental groups were compared with the values in control cultures using Student t-test. For pooling data from multiple experiments and comparing differences between groups, Wilcoxon signed rank test was performed. A p value G 0.05 was considered significant.
RESULTS
The Expression of TGFA1 and TGFA2 During Experimental Autoimmune Encephalomyelitis In Vivo
The incidence of overt EAE in Dark Agouti rats immunized with rMOG/CFA was 100% (n = 20), and the median time of disease onset was day 11 postimmunization (pi). Most rats exhibited a chronic relapsing EAE disease course characterized by rapid development of severe tetraparesis (up to clinical score of 4Y5), spontaneous partial remission (disease score 1Y2), followed by another severe relapse (Fig. 1A) . Only 2 animals followed a chronic progressive disease without remission during the experimental period.
In the lumbar spinal cord of normal control rats, constitutive levels of both TGFA1 and TGFA2 mRNA were detected (Fig. 1B) . On the protein level, TGFA2 immunoreactivity was located in neurons (not shown) and in white matter astrocytes of the spinal cord (Fig. 2B , K, L), whereas TGFA1 was restricted to the meninges (Fig. 2A) . After immunization, TGFA1 transcripts increased consistently, even at the onset of clinical disease (day 10 pi), and remained elevated above baseline at all the time points checked with a slight tendency to decrease after the peak of the first attack (day 13) (Fig. 1B, left panel) . In contrast, TGFA2 mRNA expression decreased at the early stage (day 10 pi) and around the peak of disease (day 13), returned to baseline levels during the partial remission phase (day 17), and decreased slightly again during relapse (day 27) (Fig. 1B, right panel) . Downregulation of TGFA2 was more profound during the first bout at day 10 compared with the second one at day 27 (p G 0.05). Similar results were observed also in an acute form of EAE induced in Lewis rats by immunization with MBP (not shown). These findings show that during EAE, TGFA2, and TGFA1 mRNA are reciprocally regulated. This could be confirmed on the protein level by immunohistochemistry. TGFA2 expression decreased consistently compared with control ( Fig. 2B, G) . In contrast, TGFA1 immunoreactivity increased beginning on day 10 pi and was detectable during the whole course of EAE (Fig. 2D ). Perivascular and submeningeal infiltrating cells, but also intraparenchymal cells, expressed TGFA1. Staining of serial section showed colocalization of TGFA1 with infiltrating T cells (B115-1+ cells; Fig. 2F ) and macrophages (ED1+; Fig. 2E ) and also, especially in the late phase of disease, with GFAP+ astrocytes (Fig. 2H) .
The Influence of Cytokines on TGFA1 and TGFA2 Production by Astrocytes In Vitro
To further corroborate our in vivo findings, and to characterize the regulation of TGFA1 and TGFA2 production, TGFA1 and TGFA2 secretion was investigated in vitro in supernatants of purified astrocyte cultures. Cells were treated for 48 hours with control medium, LPS, and cytokines (IFN-F, TNF->, IL-1A, IL-18, IL-10), known to be secreted in the central nervous system during EAE, and culture supernatants were analyzed by enzyme-linked immunosorbent assay specific for TGFA1 and TGFA2. Both TGFA1 and TGFA2 were produced by astrocytes under basal conditions and were downregulated by treatment with IFN-F (10, 50, 100 ng/mL; p G 0.05) (Fig. 3 ) and LPS (10, 100 ng/mL; p G 0.05) (not shown). TNF-> (10, 100 ng/mL) showed an inhibitory effect on TGFA2 (Fig. 3A , p G 0.05), but did not affect TGFA1 (Fig. 3B) . No modulatory effect on TGFA1 and TGFA2 secretion was observed when astrocytes were cultured with IL-10 (0.2Y20 ng/mL), IL-18 (0.1Y100 ng/mL), or IL-1A (0.1Y100 ng/mL). To further support the biologic relevance of the downregulatory effects of LPS, IFN-F, and TNF->, we excluded a simple toxic effect by investigating cell death through propidium iodide incorporation. Treatment of astrocytes with IFN-F and TNF-> did not affect cell viability, whereas LPS showed a significant toxic effect when compared with control culture (not shown).
Taken together, these findings indicate that some stimuli (like IFN-F) affect simultaneously the release of TGFA1 and 2, whereas other stimuli like TNF-> act selectively on one of these isoforms inhibiting TGFA2 secretion only, suggesting a differential regulatory pathway.
The Influence of Microglia on Astrocytic TGFA1 and TGFA2 Secretion
Because microglia are a potent intrinsic source of cytokines in the central nervous system and have multiple regulatory effects in the initiation and termination of EAE, we next investigated whether, in addition to T cell-derived cytokines, microglia can modify TGFA2 and TGFA1 secretion by astrocytes in vitro. To later extend these cell culture studies by T cell proliferation assays (see subsequently), we prepared glial cells from Lewis rats because permanent Lewis, but not Dark Agouti, T cell lines are available in our laboratory. Cocultures of increasing numbers of microglia with constant numbers of astrocytes progressively reduced the levels of TGFA2 and, at the same time, progressively increased the levels of TGFA1 compared with the secretion of TGFA2 and TGFA1 by cultures of astrocytes alone (Fig. 4A) . Thus, the in vivo findings could be mimicked under these in vitro conditions.
To determine whether this regulatory activity was mediated by cell contact-dependent mechanisms or by soluble factors, we cultured astrocytes and microglia in dual-chamber culture wells, and we found that the inhibitory and the stimulatory effect on TGFA2 and TGFA1 secretion, respectively, were still present, indicating that this regulatory activity of microglia is mediated mostly through one or more soluble factor(s) (Fig. 4B) .
We then examined the effect of microglia-conditioned medium on TGFA1 and TGFA2 secretion by astrocytes to verify if microglia secrete these soluble factor(s) under basal condition or need the simultaneous presence of astrocytes. Compared with astrocytes stimulated with control medium, microglia-conditioned medium suppressed TGFA2 and stimulated TGFA1 secretion by astrocytes, suggesting that most of this regulatory activity is secreted by microglia alone (Fig. 4C ).
The Influence of Astrocytic TGFA2 on Microglial Immune Functions
To investigate whether TGFA2 affects antigen-presenting features of cerebral APCs, we studied the expression of major histocompatibility complex (MHC) class II and costimulatory/adhesion molecules by cultured microglia after treatment with TGFA2 and/or IFNF. Results of representative experiments are displayed in Figure 5 . Unstimulated microglia expressed CD86 and low levels of CD54 (ICAM-1) and CD40 and did not constitutively express MHC class II (OX17) and CD80. In accordance with previous studies, treatment of microglia with IFNF induced expression of MHC-II and enhanced expression of CD54, CD40, and CD86 (22) . As a novel finding, we show here that TGFA2 downregulated constitutive CD86 expression (MFI 552 versus 44; 72% versus 51% positive cells). Moreover, TGFA2 attenuated IFNF-induced expression of CD86 (MFI 367 versus 27; 63% versus 55% positive cells), MHC class II (41% versus 19% positive cells), and CD54 (81% versus 56% positive cells) in microglia. No significant effects were observed on CD80 and CD40 expression (not shown). Microglia express CD40 and CD80 in vivo in EAE and multiple sclerosis lesions (23) , and in vitro a selective regulation of microglial MHC class II and costimulatory/ adhesion molecules has been described in the mouse model (24) . In this study, IFNF and LPS failed to induce CD80, in line with our results.
Following the line that TGFA2 downregulates cytokineinduced microglial expression of MHC class II and adhesion/ costimulatory molecules, we next assessed a related central function of microglia, that is, their ability to present antigens for T cell activation. We analyzed the proliferation of MBPspecific T cells in response to MBP presented by microglia that were pretreated with control medium, IFNF, TGFA2, or both IFNF, and TGFA2. As expected, antigen presentation by IFNF preactivated microglia consistently increased T cell proliferation when compared with control medium-treated microglia (Fig. 6) . Strikingly, coincubation with TGFA2 neutralized the stimulating effect of IFNF, supporting the concept that TGFA2 may attenuate immune responses. In contrast, no effect on T cell proliferation was observed by treating microglia with TGFA2 alone.
DISCUSSION
The principal finding of our study is that the constitutive expression of the immunosuppressive cytokine TGFA2 in the central nervous system is downregulated during acute inflammatory stages of chronic-relapsing MOG-EAE. Decline of TGFA2 expression in EAE contrasts to the increased expression of TGFA1 (25) , indicating that these TGFA isoforms are reciprocally regulated during central nervous system autoimmunity. Peress et al reported on the expression of TGFA isoforms in multiple sclerosis lesions and showed that TGFA2 was selectively expressed by astrocytes in the normal white matter consistent with our findings (26) . The observed suppression of astrocytic TGFA2 expression in vivo could be mimicked in vitro by application of the proinflammatory cytokines IFN-F and TNF->, by coculture with activated microglia, and by microglia-conditioned medium. Moreover, TGFA2 in vitro downregulated some microglial Ag-presenting properties. We conclude that local downregulation of TGFA2 could be one mechanism providing the grounds for the spread of inflammation during central nervous system autoimmunity. This notion is further supported by the following evidence: 1) TGFA2 inhibits the migration of lymphocytes into the central nervous system in vivo in a dose-dependent fashion (8) ; 2) at the time of T cell infiltration in EAE, astrocytic TGFA2 expression was in fact significantly decreased in vivo (this study); and 3) supplementation with TGFA2 ameliorated clinical disease in chronic relapsing EAE in mice (27) . TGFA2 has long been known to underlie regulation by activated T cells (28) . The humoral factors signaling TGFA2 regulation, however, were not yet elucidated. In the present study, we could identify the cytokines IFN-F and TNF-> as profound suppressors of TGFA2 in astrocytes. In fact, infiltrating inflammatory cells express these proinflammatory cytokines in vivo within acute EAE lesions (29, 30) and thereby could locally suppress TGFA2 activity. In search for other cell types crucial in TGFA2 regulation, we found that microglia play a decisive role. By culturing astrocytes together with microglia, we were able to mimic in vitro the reciprocal regulation of the TGFA1 and TGFA2 observed in vivo. In our experiments, we used neonatal microglia that more closely resemble activated microglia, which develop in response to central nervous system injury or inflammation (22, 31, 32) . The regulatory function of microglia on astrocytic TGFA1/TGFA2 secretion was mediated through soluble factors and did not require direct cellular contact. Most of this activity was secreted constitutively by cultured neonatal microglia. Interestingly, IFNF also reduced rather than increased TGFA1 production in cultured astrocytes. Thus, it appears that other proinflammatory cytokines such as IL-1> stimulate TGFA1 synthesis in EAE as suggested by a previous study (33) .
To further explore the functional role of TGFA2 in the central nervous system and to study reciprocal microglia/ astrocytic interactions, we examined its influence on antigen presentation features of cultured microglia. In an in vitro phagocytosis assay of degenerating optic and sciatic nerves, TGFA2 profoundly suppressed the phagocytic properties of microglia and macrophages (6) . We now show that TGFA2 also mitigates the expression of costimulatory immune molecules on resting and activated microglia such as MHC class II molecules, CD54 and CD86. MHC class II molecules together with costimulatory (CD86) and adhesion (CD54) molecules are required for initiating T cell responses during the APCYT cell interaction. Thereby, naBve and/or effector T cells proliferate and are primed to release proinflammatory cytokines. Functionally, we could demonstrate that TGFA2 downregulated the ability of IFNF-activated microglia to restimulate encephalitogenic MBP-specific T cells by reducing their proliferation in response to MBP. Thus, our present findings demonstrate that TGFA2 can interfere with the T cell stimulatory potential of microglia. Similar effects of TGFA2 on APC functions have been shown for peritoneal macrophages (11, 34) . Moreover, TGFA2 drives gene expression of microglia to an antiinflammatory phenotype (35) and induces microglia to secrete a chemotactic and differentiation factor for oligodendrocyte precursors, promoting remyelination (36) . Therefore, it is tempting to speculate that the transient downregulation of TGFA2 in astrocytes during EAE allows microglia to efficiently present antigen to invading T cells, thereby augmenting the local immune response.
In conclusion, our data suggest that astrocytic TGFA2 might play a pivotal role in the regulation of central nervous system-specific immune responses through the modulation of microglial APC features and blockade of phagocytosis (6) . Furthermore, the differential regulation of TGFA1 and TGFA2 both in vivo and in vitro as shown in this study argues for different roles in neuroinflammation of these homologous yet functionally different cytokines. TGFA2 may be pivotal in sustaining immune tolerance also in the central nervous system. 
